INTRODUCTION
Gastric cancer, death, tumor, cancer, PD, tumors
GASTRIC CANCER, TUMOR, CANCER, CPS, TUMORS
Gastric cancer (GC) is the fifth most commonly diagnosed cancer and the fourth leading cause of cancer‐related death worldwide.CheckMate 649 is the largest, randomized phase III study of first‐line PD‐1 inhibitor‐based therapies in patients with unresectable advanced or metastatic, nonHER2‐positive GC/GEJC/EAC. In the primary analysis, nivolumab plus chemotherapy showed superior OS benefit vs chemotherapy alone in patients whose tumors expressed programmed death (PD) ligand 1 (L1) combined positive score (CPS) ≥5 (hazard ratio [HR] 0.71, A meta‐analysis of immune checkpoint inhibitor monotherapy for the treatment of GC/GEJC indicated that Asian patients as a subgroup had greater OS benefit than non‐Asian patients; this benefit has also been observed in other tumor types.